Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-05-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: acutesubjectscontrastdayshours
  Phrases that lowered it: allergenmultipleopen labelvalueinjection
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 40% (lowers risk) · Drug's FDA history
• Primary purpose: diagnostic (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 127 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor's past trials: 369 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports with a death: 20% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gadobutrol Enhanced MRA of the Renal Arteries NCT01344460 · started 2011 · scored riskier than 33% of active trials completed
• Gadobutrol Magnevist-controlled Body Study NCT01050829 · started 2010 · scored riskier than 40% of active trials completed
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) NCT05915728 · started 2023 · scored riskier than 30% of active trials completed
• Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) NCT01890434 · started 2013 · scored riskier than 48% of active trials completed
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems NCT05915702 · started 2023 · scored riskier than 19% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.